TCLIF Stock Chart & Stats
$0.53
$0.21(66.25%)
At close: 4:00 PM EDT
$0.53
$0.21(66.25%)
Day’s Range― - ―
52-Week Range$0.32 - $0.53
Previous CloseN/A
Volume500.00
Average Volume (3M)0.00
Market Cap
$50.06M
Enterprise Value$37.71
Total Cash (Recent Filing)$3.38M
Total Debt (Recent Filing)$5.09M
Price to Earnings (P/E)―
Beta3.33
Next Earnings
Oct 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)-13.53
Price to Sales (P/S)29.53
P/FCF Ratio-4.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Non‑invasive HIFU PlatformTheraclion’s Echopulse HIFU platform represents a durable product-level advantage: a non-invasive, imaging‑guided therapy addressing clinical needs. Such differentiated medical‑device technology supports long product lifecycles, clinical adoption pathways and potential recurring service and upgrade revenues.
Recent Revenue MomentumReported revenue growth indicates prior commercial traction and market demand for the company’s offerings. Sustained top‑line expansion over months can validate sales channels and adoption, improving prospects for scale if management converts early momentum into repeatable commercial processes.
Lean Operating StructureA small, focused workforce implies lower fixed overhead and greater capital efficiency, which can extend runway while the company develops commercial traction. For a capital‑constrained medical‑device firm, lean operations permit targeted R&D and market activities without large structural cost burdens.
Bears Say
Chronic Cash BurnSustained negative operating and free cash flow of approximately -€7.2M signals ongoing cash burn that will necessitate external financing to sustain operations. This persistent outflow constrains strategic investment, increases dilution risk, and puts pressure on the company’s ability to self‑fund commercial expansion.
Negative Equity And LeverageReturn to negative equity and meaningful debt relative to revenue heighten solvency risk and restrict financing flexibility. Elevated leverage for a small revenue base raises cost of capital, limits strategic optionality, and increases vulnerability to downturns or unexpected cash needs.
Structurally UnprofitableConsistent gross, operating and net losses show the cost base is not yet supported by sales. Without durable margin improvement or higher revenue scale, the business faces structural profitability challenges that undermine long‑term viability and require material operational or commercial correction.
TCLIF FAQ
What was Theraclion SA’s price range in the past 12 months?
Theraclion SA lowest stock price was $0.32 and its highest was $0.53 in the past 12 months.
What is Theraclion SA’s market cap?
Theraclion SA’s market cap is $50.06M.
When is Theraclion SA’s upcoming earnings report date?
Theraclion SA’s upcoming earnings report date is Oct 14, 2026 which is in 75 days.
How were Theraclion SA’s earnings last quarter?
Theraclion SA released its earnings results on Apr 16, 2026. The company reported -$0.061 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Theraclion SA overvalued?
According to Wall Street analysts Theraclion SA’s price is currently Overvalued.
Does Theraclion SA pay dividends?
Theraclion SA does not currently pay dividends.
What is Theraclion SA’s EPS estimate?
Theraclion SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Theraclion SA have?
Currently, no data Available
What happened to Theraclion SA’s price movement after its last earnings report?
Theraclion SA reported an EPS of -$0.061 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Theraclion SA?
Currently, no hedge funds are holding shares in TCLIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theraclion SA
Theraclion SA, established in 2004 and based in Malakoff, France, specializes in developing innovative echotherapy medical solutions. These treatments harness high-intensity focused ultrasound (HIFU) technology. Their offerings include SONOVEIN, a robotic, non-surgical echotherapy system designed for addressing varicose veins, and ECHOPULSE, a similar robotic, non-invasive solution for treating thyroid nodules and breast fibroadenoma. Furthermore, the company provides EPack, a disposable component used during procedures to protect the patient's skin and enhance image clarity.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Novacyt
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―